Abstract
The radiochemical synthesis and stability of 67Ga-deferoxamine-folate ([67Ga]Ga-DF-Folate) were examined as a function of DF-Folate concentration. Optimal labeling occurred at DF-Folate concentrations > or =2.5 microg/mL. To define the possible biological significance of variations in product formulation, the biodistribution of [67Ga]Ga-DF-Folate was examined as a function of administered deferoxamine-folate dose in an athymic mouse KB tumor model. The folate-receptor-positive KB tumors were found to concentrate the 67Ga radiolabel in a dose-dependent fashion, consistent with saturable involvement of the folate receptor in mediating tumor accumulation of the radiopharmaceutical.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Animals
-
Biomarkers, Tumor / chemical synthesis*
-
Carrier Proteins / metabolism*
-
Deferoxamine / analogs & derivatives*
-
Deferoxamine / metabolism
-
Dose-Response Relationship, Radiation
-
Folate Receptors, GPI-Anchored
-
Folic Acid / analogs & derivatives*
-
Folic Acid / metabolism
-
Gallium Radioisotopes
-
Humans
-
Isotope Labeling
-
KB Cells
-
Male
-
Mice
-
Mice, Nude
-
Radiopharmaceuticals / metabolism*
-
Receptors, Cell Surface*
-
Tissue Distribution
Substances
-
Biomarkers, Tumor
-
Carrier Proteins
-
Folate Receptors, GPI-Anchored
-
Gallium Radioisotopes
-
Radiopharmaceuticals
-
Receptors, Cell Surface
-
deferoxamine-gamma-folate conjugate
-
Folic Acid
-
Deferoxamine